In response to the rising off-label cosmetic use of GLP-1 therapies, authorities are establishing a multi-stakeholder pharmacovigilance framework to monitor long-term safety signals while promoting adherence-support programs and issuing nutritional management guidelines. Despite the clear benefits these medications offer for obesity and type 2 diabetes, emerging gastrointestinal side effects and concerns over nutritional deficiencies underscore the need for stringent marketing regulations and comprehensive public education campaigns about their risks and rewards.
Title not available for this citation.
“Limited available data indicate that glucagon-like peptide-1 (GLP-1) medications may significantly reduce weight and binge-eating symptoms among patients with binge-eating disorder.”
Title not available for this citation.
“However, experts express concern about the potential for GLP-1 medications to cause unintended harm or be misused among some individuals with eating disorders (EDs).”
Title not available for this citation.
“Liraglutide, semaglutide and tirzepatide have transformed the management of obesity.”
Title not available for this citation.
“However, dose-related gastrointestinal effects, obesity-associated nutritional insufficiencies, and poor long-term adherence may limit their long-term health benefits.”
Title not available for this citation.
“The consensus statement development was based on an initial scoping review that included searching PubMed, Embase, Web of Science, Cochrane, and Medline for relevant scientific publications.”
Title not available for this citation.
“A total of 52 consensus statements were developed, outlining key considerations for the practical management of obesity and associated complications with GBTs.”
Title not available for this citation.
“Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, represents a new class of incretin-based therapy for type 2 diabetes mellitus (T2DM), obesity, and related comorbidities.”
Title not available for this citation.
“Across studies, tirzepatide reduced glycated hemoglobin (HbA1c) by up to 2.5% and body weight by more than 20%.”
Title not available for this citation.
“It also improved cardiovascular risk factors (blood pressure, lipids, inflammation) and has demonstrated benefits in patients with heart failure with preserved ejection fraction (HFpEF) and obstructive sleep apnea (OSA),”
Title not available for this citation.
“Its safety profile is consistent with that of GLP-1 receptor agonists (GLP-1 RAs), although gastrointestinal side effects, gallbladder events, and thyroid cancer signals warrant monitoring.”
Title not available for this citation.
“We explore how excess adiposity may accelerate menarche, disrupt menstrual regularity, and increase the risk of polycystic ovary syndrome and hyperandrogenism...”
Title not available for this citation.
“Structured lifestyle interventions, including dietary modifications and regular physical activity, remain the cornerstone of managing overweight-related menstrual irregularities...”